在替诺福韦酯临床试验中，C亚型HIV-1感染患者中K65R的演变情况。 - Suppr

Suppr

超能文献

K65R development among subtype C HIV-1-infected patients in tenofovir DF clinical trials.

作者信息

Miller Michael D, Margot Nicolas, McColl Damian, Cheng Andrew K

出版信息

AIDS. 2007 Jan 11;21(2):265-6. doi: 10.1097/QAD.0b013e32801199ee.

DOI:10.1097/QAD.0b013e32801199ee

PMID:17197831

Abstract

摘要

相似文献

K65R development among subtype C HIV-1-infected patients in tenofovir DF clinical trials.在替诺福韦酯临床试验中，C亚型HIV-1感染患者中K65R的演变情况。

AIDS. 2007 Jan 11;21(2):265-6. doi: 10.1097/QAD.0b013e32801199ee.

Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovir.未使用替诺福韦的治疗方案失败的HIV感染患者中K65R突变的临床和基因型相关性

J Med Virol. 2006 May;78(5):535-41. doi: 10.1002/jmv.20573.

K65R, TAMs and tenofovir.K65R、肿瘤相关巨噬细胞与替诺福韦

AIDS Rev. 2004 Jan-Mar;6(1):22-33.

The K65R mutation in HIV-1 reverse transcriptase.HIV-1逆转录酶中的K65R突变。

J HIV Ther. 2004 May;9(2):25-7.

Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization.HIV-1逆转录酶突变K65R流行率的增加与替诺福韦的使用相关。

Antivir Ther. 2004 Oct;9(5):827-8.

Tenofovir disoproxil fumarate.富马酸替诺福韦二吡呋酯

Clin Infect Dis. 2003 Oct 1;37(7):944-50. doi: 10.1086/378068. Epub 2003 Sep 12.

Long-term follow-up of patients taking tenofovir DF with low-level HIV-1 viremia and the K65R substitution in HIV-1 RT.对接受替诺福韦酯治疗且HIV-1病毒血症水平较低以及HIV-1逆转录酶存在K65R替代的患者进行长期随访。

AIDS. 2007 Mar 30;21(6):761-3. doi: 10.1097/QAD.0b013e3280187533.

Selection of L74V mutation in reverse transcriptase of HIV-1 subtype D by a tenofovir DF-lamivudine based regimen.基于替诺福韦酯-拉米夫定的治疗方案对HIV-1 D亚型逆转录酶中L74V突变的选择

AIDS. 2007 Nov 30;21(18):2551-2. doi: 10.1097/QAD.0b013e32827b1499.

Effect of tenofovir subtraction on HIV plasma viraemia, CD4+ T-cell count and resistance in a patient with baseline K65R and M184V mutations.替诺福韦减量对一名基线存在K65R和M184V突变患者的HIV血浆病毒血症、CD4+ T细胞计数及耐药性的影响

Antivir Ther. 2008;13(5):735-7.

The rise and fall of K65R in a Portuguese HIV-1 Drug Resistance database, despite continuously increasing use of tenofovir.在葡萄牙的一个HIV-1耐药性数据库中，尽管替诺福韦的使用持续增加，但K65R仍有起伏。

Infect Genet Evol. 2009 Jul;9(4):683-8. doi: 10.1016/j.meegid.2008.10.013. Epub 2008 Nov 6.

引用本文的文献

HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon.在资源有限的环境下，对于正在从一线方案转换至二线方案的大量治疗的患者，进行 HIV-1 耐药性检测至关重要：来自喀麦隆常规临床实践的证据。

BMC Infect Dis. 2019 Mar 12;19(1):246. doi: 10.1186/s12879-019-3871-0.

HIV-1 drug resistance in recently HIV-infected pregnant mother's naïve to antiretroviral therapy in Dodoma urban, Tanzania.坦桑尼亚多多马市近期感染艾滋病毒且未接受过抗逆转录病毒治疗的孕妇中的HIV-1耐药性情况

BMC Infect Dis. 2013 Sep 21;13:439. doi: 10.1186/1471-2334-13-439.

Targeting of the purine biosynthesis host cell pathway enhances the activity of tenofovir against sensitive and drug-resistant HIV-1.靶向嘌呤生物合成宿主细胞途径增强了替诺福韦对敏感和耐药 HIV-1 的活性。

J Infect Dis. 2013 Dec 15;208(12):2085-94. doi: 10.1093/infdis/jit395. Epub 2013 Aug 6.

HIV-1 Genetic Variability and Clinical Implications.HIV-1基因变异性及其临床意义。

ISRN Microbiol. 2013 Jun 17;2013:481314. doi: 10.1155/2013/481314. Print 2013.

HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir.HIV-1 亚型是包含替诺福韦的联合抗逆转录病毒治疗的 HIV-1 患者中逆转录酶突变 K65R 的独立预测因子。

Antimicrob Agents Chemother. 2013 Feb;57(2):1053-6. doi: 10.1128/AAC.01668-12. Epub 2012 Nov 26.

Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring.无病毒学监测情况下，一线抗逆转录病毒治疗中使用替诺福韦而非齐多夫定的成本效益。

PLoS One. 2012;7(8):e42834. doi: 10.1371/journal.pone.0042834. Epub 2012 Aug 8.

Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy.意大利B型与最常见的非B型HIV-1亚型（C型、F型和CRF02_AG）之间耐药性的比较分析。

AIDS Res Hum Retroviruses. 2012 Oct;28(10):1285-93. doi: 10.1089/AID.2011.0142. Epub 2012 Apr 18.

Factors influencing the emergence and spread of HIV drug resistance arising from rollout of antiretroviral pre-exposure prophylaxis (PrEP).影响抗逆转录病毒药物预先暴露预防（PrEP）推出后 HIV 耐药性出现和传播的因素。

PLoS One. 2011 Apr 15;6(4):e18165. doi: 10.1371/journal.pone.0018165.

The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications.HIV-1逆转录酶中的K65R突变：遗传屏障、耐药谱及临床意义

HIV Ther. 2009 Nov 1;3(6):583-594. doi: 10.2217/hiv.09.40.

Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria.在尼日利亚，接受一线抗逆转录病毒治疗失败的 HIV 感染患者中，伴有 K65R 突变的临床和基因型发现。

J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):228-34. doi: 10.1097/QAI.0b013e3181b06125.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验